Company: ARMP
Filing Date: 2025-12-01
Form Type: 424B5
Source: 0001104659-25-117382
Chunk: 30

Company: Armata Pharmaceuticals, Inc.
Filing Date: 2025-12-01
Form: 424B5
Chunk 30
---
 document,
all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded
for purposes of this prospectus supplement to the extent that a statement contained herein or in any other subsequently filed document
which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified
or superseded shall not be deemed, except as so modified or amended, to constitute a part of this prospectus supplement.

We will furnish without charge to you, on written
or oral request, a copy of any or all of the documents incorporated by reference, including exhibits to these documents. You should direct
any requests for documents by writing us at 5005 McConnell Avenue, Los Angeles, California 90066, Attention: SVP Finance, or telephoning
us at (310) 665-2928.

The SEC maintains a website that contains reports,
proxy and information statements, and other information regarding issuers that file electronically with the SEC (http://www.sec.gov).
In addition, we maintain a website at www.armatapharma.com. Information contained in our website does not constitute a part
of this prospectus supplement or the base prospectus.

<div align='center'>S-23

PROSPECTUS

$100,000,000

Common Stock

Preferred Stock

Debt Securities

Warrants

Units</div>

From time to time, we may sell up to an aggregate
of $100,000,000 of our common stock, preferred stock, debt securities, warrants or units in any combination of the foregoing, in amounts,
at prices and on terms described in one or more supplements to this prospectus. We may also authorize one or more free writing prospectuses
to be provided to you in connection with these offerings.

Our common stock is traded on the New York Stock
Exchange (the “NYSE”) American under the trading symbol “ARMP.” On August 11, 2025, the last reported sale price
of our common stock on the NYSE American was $2.36.

The preferred stock, debt securities, warrants
and units described in this prospectus have not been approved for listing on any market or exchange, and we have not made any application
for such listing.

This prospectus describes the general terms of
the securities we may offer and the general manner in which we may offer these securities. Each time we sell securities described herein,
we will provide prospective investors with